Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has a beta value of 0.58 and has seen 2.51 million shares traded in the last trading session. The company, currently valued at $276.31M, closed the last trade at $4.05 per share which meant it lost -$0.38 on the day or -8.47% during that session. The CRVS stock price is -146.91% off its 52-week high price of $10.00 and 56.79% above the 52-week low of $1.75.
The consensus among analysts is that Corvus Pharmaceuticals Inc (CRVS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Sporting -8.47% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CRVS stock price touched $4.05 or saw a rise of 10.6%. Year-to-date, Corvus Pharmaceuticals Inc shares have moved -24.21%, while the 5-day performance has seen it change 13.74%. Over the past 30 days, the shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have changed 41.29%.
Wall Street analysts have a consensus price target for the stock at $13, which means that the shares’ value could jump 68.85% from current levels. The projected low price target is $13.0 while the price target rests at a high of $13.0. In that case, then, we find that the current price level is -220.99% off the targeted high while a plunge would see the stock gain -220.99% from current levels.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
The company’s shares have lost -53.82% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 8.47% over the past 5 years. Earnings growth for 2025 is a modest 50.68% while over the next 5 years, the company’s earnings are expected to increase by 17.07%.
CRVS Dividends
Corvus Pharmaceuticals Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
The top two institutional holders are ORBIMED ADVISORS LLC with over 6.94 million shares worth more than $12.64 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 11.6289% of shares outstanding.
The other major institutional holder is SAMLYN CAPITAL, LLC, with the holding of over 6.12 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.14 million and represent 10.2546% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 2.32% shares in the company for having 1.58 shares of worth $6.41 million while later fund manager owns 793.14 shares of worth $3.22 million as of Dec 31, 2024 , which makes it owner of about 1.16% of company’s outstanding stock.
